Table I.
Variable | Summary (% of n = 6676) | Missing (% of n = 6676) |
---|---|---|
Age, mean [range] | 81.3 [29–101] | 0 (0%) |
Women, n (%) | 3085 (46.2%) | 22 (0.3%) |
Weight (kg), mean [range] | 74.0 [32.0–190.0] | 131 (2.0%) |
Height (m), mean [range] | 1.6 [1.1–2.4] | 159 (2.4%) |
NYHA | 42 (0.6%) | |
Class I, n (%) | 185 (2.8%) | |
Class II, n (%) | 1116 (16.7%) | |
Class III, n (%) | 4186 (62.7%) | |
Class IV, n (%) | 1147 (17.2%) | |
Creatinine, μmol/L, mean [range] | 114.3 [29.0–1044.0] | 73 (1.1%) |
Creatinine greater than 200 μmol/L, n (%) | 379 (5.7%) | 73 (1.1%) |
LVEF | 59 (0.88%) | |
≥50%, n (%) | 4074 (61.0%) | |
30–49%, n (%) | 1929 (28.9%) | |
<30%, n (%) | 614 (9.2%) | |
Extracardiac arteriopathy, n (%) | 1572 (23.5%) | 88 (1.3%) |
Diabetes | 35 (0.52%) | |
Dietary control, n (%) | 290 (4.3%) | |
Oral medicine, n (%) | 884 (13.2%) | |
Insulin, n (%) | 363 (5.4%) | |
Dialysis, n (%) | 127 (1.9%) | 66 (0.99%) |
MI | 33 (0.49%) | |
Within 90 days of TAVI, n (%) | 153 (2.3%) | |
Within 30 days of TAVI, n (%) | 65 (0.97%) | |
Within 24 hours of TAVI, n (%) | 6 (0.09%) | |
Procedure urgency | 7 (0.10%) | |
Elective, n (%) | 5853 (87.7%) | |
Urgent, n (%) | 772 (11.6%) | |
Emergency, n (%) | 35 (0.52%) | |
Salvage, n (%) | 9 (0.13%) | |
Valve type | 31 (0.46%) | |
Edwards SAPIEN Valve, n (%) | 3684 (55.2%) | |
Medtronic CoreValve, n (%) | 2735 (41.0%) | |
Access route | 13 (0.19%) | |
TF access, n (%) | 4965 (74.4%) | |
Transapical access, n (%) | 1064 (15.9%) | |
Chronic lung disease, n (%) | 1879 (28.1%) | 94 (1.4%) |
Cerebrovascular disease, n (%) | 1139 (17.1%) | 35 (0.52%) |
Previous cardiac surgery, n (%) | 2087 (31.3%) | 35 (0.52%) |
Critical preoperative state, n (%) | 110 (1.6%) | 81 (1.2%) |
PA systolic >60 mmHg | 785 (11.8) | 1860 (27.9%) |
LMS >50% or Triple vessel disease, n (%) | 887 (13.3%) | 74 (1.1%) |
LMS, Left main stem disease; MI, myocardial infarction; NYHA, New York Heart Association Functional Classification; PA, pulmonary artery; TF, transfemoral access route.